1 | At time of Diagnosis
Liquid biopsy provides insight into the origins and severity of the patient’s cancer(s).
Liquid biopsy can identify which patients and tumors will benefit from immunotherapy. Patient outcomes are optimal when first-line treatments align with tumor biology.
Oncologists should know the status of PD-L1 (NSCLC) and MSI-H (CRC) to determine if first-line immunotherapy treatments are warranted.
MSI-H testing is vitally important to avoid chemotherapy harm since chemotherapy is ineffective in MSI-H cancers.